Emergent BioSolutions Gains FDA Nod and WHO Evaluation

Emergent Biosolutions (EBS) just unveiled an update.

Emergent BioSolutions Inc. recently announced that the U.S. FDA has approved the expansion of the indication for its ACAM2000® vaccine, now including immunization against mpox disease for high-risk individuals. This comes on the heels of Emergent’s move to have the vaccine evaluated by the WHO for emergency use during the mpox outbreak.

Learn more about EBS stock on TipRanks’ Stock Analysis page.